Transcriptomic analysis of pre- and post-treatment GBM tumors (GBM-28 vs. GBM-37)

Finding a novel prognostic marker and therapeutic target for aggressive GBM is necessary. By analyzing pre- and post-treatment tumors from a GBM patient who experienced a very aggressive tumor recurrence after receiving concurrent chemoradiotherapy with temozolomide, we discovered a novel prognostic marker for aggressive mesenchymal GBM Primary cell cultures (< 5 passages) derived from brain tumor tissues were subjected for cDNA microarray analysis to analyze the transcriptomic alteration upon conventional treatment and to discover a novel key regulator responsible for such an aggressive tumor progression